These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11909727)

  • 1. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes.
    Mehrotra MM; Heath JA; Rose JW; Smyth MS; Seroogy J; Volkots DL; Ruhter G; Schotten T; Alaimo L; Park G; Pandey A; Scarborough RM
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1103-7. PubMed ID: 11909727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.
    Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Seroogy J; Volkots D; Pandey A; Scarborough RM
    Bioorg Med Chem Lett; 2001 May; 11(10):1289-92. PubMed ID: 11392539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.
    Pandey A; Seroogy J; Volkots D; Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Scarborough RM
    Bioorg Med Chem Lett; 2001 May; 11(10):1293-6. PubMed ID: 11392540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
    J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists.
    Liverton NJ; Armstrong DJ; Claremon DA; Remy DC; Baldwin JJ; Lynch RJ; Zhang G; Gould RJ
    Bioorg Med Chem Lett; 1998 Mar; 8(5):483-6. PubMed ID: 9871603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
    Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
    J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines.
    Confalone PN; Jin F; Mousa SA
    Bioorg Med Chem Lett; 1999 Jan; 9(1):55-8. PubMed ID: 9990456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of 1,4-benzodioxine derivatives as novel platelet aggregation inhibitors.
    Xie Z; Zhao L; Ding X; Kong Y; Li Z
    Future Med Chem; 2018 Feb; 10(4):367-378. PubMed ID: 29380625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
    J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
    Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
    Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
    J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.
    Xue CB; Wityak J; Sielecki TM; Pinto DJ; Batt DG; Cain GA; Sworin M; Rockwell AL; Roderick JJ; Wang S; Orwat MJ; Frietze WE; Bostrom LL; Liu J; Higley CA; Rankin FW; Tobin AE; Emmett G; Lalka GK; Sze JY; Di Meo SV; Mousa SA; Thoolen MJ; Racanelli AL; Olson RE
    J Med Chem; 1997 Jun; 40(13):2064-84. PubMed ID: 9207948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Acylimino-3H-thiazoline derivatives: a novel template for platelet GPIIb/IIIa receptor antagonists.
    Manaka A; Sato M; Aoki M; Tanaka M; Ikeda T; Toda Y; Yamane Y; Nakaike S
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1031-5. PubMed ID: 11327582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
    Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
    Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.
    Lawson EC; Hoekstra WJ; Addo MF; Andrade-Gordon P; Damiano BP; Kauffman JA; Mitchell JA; Maryanoff BE
    Bioorg Med Chem Lett; 2001 Oct; 11(19):2619-22. PubMed ID: 11551763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.
    Egbertson MS; Cook JJ; Bednar B; Prugh JD; Bednar RA; Gaul SL; Gould RJ; Hartman GD; Homnick CF; Holahan MA; Libby LA; Lynch JJ; Lynch RJ; Sitko GR; Stranieri MT; Vassallo LM
    J Med Chem; 1999 Jul; 42(13):2409-21. PubMed ID: 10395482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally active GPIIb/IIIa antagonists: synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4.
    Kitamura S; Fukushi I; Miyawaki T; Kawamura M; Terashita E; Naka T
    Chem Pharm Bull (Tokyo); 2001 Mar; 49(3):268-77. PubMed ID: 11253915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.